Global Non-Hodgkin's Lymphoma Epidemiology and Patient Flow Analysis - 2012

Fore Pharma announced the results of its Non-Hodgkin's Lymphoma patient population study in a new report ‘Global Non-Hodgkin's Lymphoma Epidemiology and Patient Flow Analysis - 2012’. The report provides insights into Non-Hodgkin's Lymphoma epidemiology, Non-Hodgkin's Lymphoma diagnosed patients, and Non-Hodgkin's Lymphoma treatment rate for top seven pharmaceutical markets. The study measures key indicators such as prevalence of Non-Hodgkin's Lymphoma derived from epidemiological analysis, percentage of patients diagnosed with Non-Hodgkin's Lymphoma, and percentage of patients treated with Non-Hodgkin's Lymphoma therapy.

The study helps executives estimate Non-Hodgkin's Lymphoma market potential, assess unmet need, develop drug forecasting models, and build population-based health management frameworks. The information presented in this study is used to evaluate market opportunities, effectively identify target patient population, and align marketing decisions.

The report provides estimates and forecasts of Non-Hodgkin's Lymphoma prevalence, Non-Hodgkin's Lymphoma diagnosis rate, and Non-Hodgkin's Lymphoma treatment rate for the period 2012-2019. The information is presented by leading geographies including the US, Germany, France, Spain, Italy, UK, and Japan. The study design is based on collection and interpretation of data from registries, scientific journals and literatures, government databases and other secondary sources.

Key Features of the Report:
- Non-Hodgkin's Lymphoma: Disease Definition
- Non-Hodgkin's Lymphoma Patient Flow
- Non-Hodgkin's Lymphoma Prevalence
- Non-Hodgkin's Lymphoma Diagnosed Patients
- Non-Hodgkin's Lymphoma Treated Patients SHOW LESS READ MORE >

1. Non-Hodgkin's Lymphoma: Disease Definition
2. Global Non-Hodgkin's Lymphoma Patient Flow
2A. Global Non-Hodgkin's Lymphoma Prevalence
2B. Global Non-Hodgkin's Lymphoma Diagnosed Patients
2C. Global Non-Hodgkin's Lymphoma Treated Patients
3. Non-Hodgkin's Lymphoma Patient Flow in the US
3A. Non-Hodgkin's Lymphoma Prevalence in the US
3B. Non-Hodgkin's Lymphoma Diagnosed Patients in the US
3C. Non-Hodgkin's Lymphoma Treated Patients in the US
4. Non-Hodgkin's Lymphoma Patient Flow in Europe
4A. Non-Hodgkin's Lymphoma Prevalence in Europe
4B. Non-Hodgkin's Lymphoma Diagnosed Patients in Europe
4C. Non-Hodgkin's Lymphoma Treated Patients in Europe
5. Non-Hodgkin's Lymphoma Patient Flow in Germany
5A. Non-Hodgkin's Lymphoma Prevalence in Germany
5B. Non-Hodgkin's Lymphoma Diagnosed Patients in Germany
5C. Non-Hodgkin's Lymphoma Treated Patients in Germany
6. Non-Hodgkin's Lymphoma Patient Flow in France
6A. Non-Hodgkin's Lymphoma Prevalence in France
6B. Non-Hodgkin's Lymphoma Diagnosed Patients in France
6C. Non-Hodgkin's Lymphoma Treated Patients in France
7. Non-Hodgkin's Lymphoma Patient Flow in Spain
7A. Non-Hodgkin's Lymphoma Prevalence in Spain
7B. Non-Hodgkin's Lymphoma Diagnosed Patients in Spain
7C. Non-Hodgkin's Lymphoma Treated Patients in Spain
8. Non-Hodgkin's Lymphoma Patient Flow in Italy
8A. Non-Hodgkin's Lymphoma Prevalence in Italy
8B. Non-Hodgkin's Lymphoma Diagnosed Patients in Italy
8C. Non-Hodgkin's Lymphoma Treated Patients in Italy
9. Non-Hodgkin's Lymphoma Patient Flow in UK
9A. Non-Hodgkin's Lymphoma Prevalence in UK
9B. Non-Hodgkin's Lymphoma Diagnosed Patients in UK
9C. Non-Hodgkin's Lymphoma Treated Patients in UK
10. Non-Hodgkin's Lymphoma Patient Flow in Japan
10A. Non-Hodgkin's Lymphoma Prevalence in Japan
10B. Non-Hodgkin's Lymphoma Diagnosed Patients in Japan
10C. Non-Hodgkin's Lymphoma Treated Patients in Japan
11. Appendix
12. Research Methodology
12A. Sources

Table 1: Global Non-Hodgkin's Lymphoma Patient Flow (2012)
Table 2: Global Non-Hodgkin's Lymphoma Patient Flow Forecast (2012-2019)
Table 3: Non-Hodgkin's Lymphoma Patient Flow in the US (2012)
Table 4: Non-Hodgkin's Lymphoma Patient Flow Forecast in the US (2012-2019)
Table 5: Non-Hodgkin's Lymphoma Patient Flow in Europe (2012)
Table 6: Non-Hodgkin's Lymphoma Patient Flow Forecast in Europe (2012-2019)
Table 7: Non-Hodgkin's Lymphoma Patient Flow in Germany (2012)
Table 8: Non-Hodgkin's Lymphoma Patient Flow Forecast in Germany (2012-2019)
Table 9: Non-Hodgkin's Lymphoma Patient Flow in France (2012)
Table 10: Non-Hodgkin's Lymphoma Patient Flow Forecast in France (2012-2019)
Table 11: Non-Hodgkin's Lymphoma Patient Flow in Spain (2012)
Table 12: Non-Hodgkin's Lymphoma Patient Flow Forecast in Spain (2012-2019)
Table 13: Non-Hodgkin's Lymphoma Patient Flow in Italy (2012)
Table 14: Non-Hodgkin's Lymphoma Patient Flow Forecast in Italy (2012-2019)
Table 15: Non-Hodgkin's Lymphoma Patient Flow in UK (2012)
Table 16: Non-Hodgkin's Lymphoma Patient Flow Forecast in UK (2012-2019)
Table 17: Non-Hodgkin's Lymphoma Patient Flow in Japan (2012)
Table 18: Non-Hodgkin's Lymphoma Patient Flow Forecast in Japan (2012-2019)

Figure 1: Global Non-Hodgkin's Lymphoma Patient Flow (2012)
Figure 2: Global Non-Hodgkin's Lymphoma Patient Flow Forecast (2012-2019)
Figure 3: Non-Hodgkin's Lymphoma Patient Flow in the US (2012)
Figure 4: Non-Hodgkin's Lymphoma Patient Flow Forecast in the US (2012-2019)
Figure 5: Non-Hodgkin's Lymphoma Patient Flow in Europe (2012)
Figure 6: Non-Hodgkin's Lymphoma Patient Flow Forecast in Europe (2012-2019)
Figure 7: Non-Hodgkin's Lymphoma Patient Flow in Germany (2012)
Figure 8: Non-Hodgkin's Lymphoma Patient Flow Forecast in Germany (2012-2019)
Figure 9: Non-Hodgkin's Lymphoma Patient Flow in France (2012)
Figure 10: Non-Hodgkin's Lymphoma Patient Flow Forecast in France (2012-2019)
Figure 11: Non-Hodgkin's Lymphoma Patient Flow in Spain (2012)
Figure 12: Non-Hodgkin's Lymphoma Patient Flow Forecast in Spain (2012-2019)
Figure 13: Non-Hodgkin's Lymphoma Patient Flow in Italy (2012)
Figure 14: Non-Hodgkin's Lymphoma Patient Flow Forecast in Italy (2012-2019)
Figure 15: Non-Hodgkin's Lymphoma Patient Flow in UK (2012)
Figure 16: Non-Hodgkin's Lymphoma Patient Flow Forecast in UK (2012-2019)
Figure 17: Non-Hodgkin's Lymphoma Patient Flow in Japan (2012)
Figure 18: Non-Hodgkin's Lymphoma Patient Flow Forecast in Japan (2012-2019)